TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -142.60M | -136.78M | -131.48M | -127.50M | -111.30M |
| Total Depreciation and Amortization | 2.85M | 3.11M | 3.53M | 4.11M | 4.68M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10.11M | 8.50M | 8.03M | 7.52M | 5.85M |
| Change in Net Operating Assets | -1.10M | -1.02M | 779.00K | 5.05M | -6.40M |
| Cash from Operations | -130.73M | -126.18M | -119.14M | -110.82M | -107.18M |
| Capital Expenditure | -5.12M | -5.07M | -4.65M | -3.83M | -3.41M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 126.96M | 11.98M | -70.59M | -48.79M | -74.59M |
| Cash from Investing | 121.84M | 6.91M | -75.25M | -52.61M | -77.99M |
| Total Debt Issued | 32.46M | 32.46M | 32.46M | 32.46M | -- |
| Total Debt Repaid | -17.14M | -17.14M | -17.14M | -17.14M | -- |
| Issuance of Common Stock | 569.00K | 1.80M | 34.92M | 35.18M | 34.82M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 29.40M | 29.40M | 157.75M | 158.27M | 128.27M |
| Cash from Financing | 45.28M | 46.51M | 207.98M | 208.77M | 163.09M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.39M | -72.77M | 13.60M | 45.33M | -22.08M |